Catalent-cell therapy manufacturer deal now complete
Bone Therapeutics subsidiary becomes part of Catalent's cell and gene therapy unit
Following an agreement Pharmaceutical Commerce originally reported being reached in late October, Catalent Pharma Solutions, Inc. has officially completed its acquisition of Bone Therapeutics’ manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), for $14.2 million USD ($12 million EUR). With the transaction closing, SCTS’ manufacturing infrastructure and production operating teams are now part of Catalent’s Cell & Gene Therapy division.
Alongside this deal, Bone Therapeutics and Catalent also entered into associated supply agreements, which state that the purchased manufacturing entity will continue to service the production of ALLOB, Bone Therapeutics’ allogeneic cell therapy product, for Bone Therapeutics and its partners. This will grant the company access to Catalent’s network of clinical and commercial manufacturing facilities.
The partnership will allow Bone Therapeutics to focus its strategy on product development from its MSC (mesenchymal stromal cell) platform of cell and gene therapeutic targets for orthopedics, among other indications.
